Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
LNTH · Nasdaq · United States · In Vitro & In Vivo Diagnostic Substances
In shortLantheus Holdings, Inc. is profitable, generates cash and carries moderate debt, with revenue stable (+0.5% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 20.2% | 84/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 15.2% | 81/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 21.4% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 13.9% | 93/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.70× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.52× | 82/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.55× | 99/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 15.74× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.61 | 90/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 23.0% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.52× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 46.5% | 0/100 |
| Operating margin volatility | 18.6% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 18.1% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | 104.3% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 425 | 935 | 1,296 | 1,534 | 1,542 |
| Cost of revenue | 238 | 353 | 587 | 546 | 600 |
| Gross profit | 188 | 582 | 710 | 988 | 942 |
| Research & development | 45 | 312 | 78 | 168 | 177 |
| Operating income | (61) | 36 | 365 | 457 | 311 |
| Interest expense | 7.8 | 7.2 | 20 | 20 | 20 |
| Pre-tax income | (75) | 27 | 411 | 431 | 314 |
| Income tax | (3.8) | (1.3) | 84 | 119 | 80 |
| Net income | (71) | 28 | 327 | 312 | 234 |
| Diluted EPS | −$1.06 | $0.40 | $4.65 | $4.36 | $3.41 |
| Diluted shares (millions) | 67 | 71 | 70 | 72 | 68 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
4.61 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026